// Biotech and Pharma Therapeutics
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
February 18, 2026 / Ionis antisense therapy / Tryngolza hypertriglyceridemia / familial chylomicronemia syndrome / triglyceride lowering treatment / chronic hepatitis B functional cure
Ionis advances its cardiometabolic pipeline with Tryngolza demonstrating significant triglyceride reductions in familial chylomicronemia syndrome and severe hypertriglyceridemia, alongside antisense therapies achieving functional cure signals in chronic hepatitis B, marking expansion into broader metabolic and hepatic disease markets.
Healthcare’s AI Obsession Is Missing the Point on Nursing Shortages
February 18, 2026 / nursing workforce shortage / AI in clinical care / nurse burnout crisis / healthcare staffing sustainability / bedside clinical judgment
AI should augment—not replace—nurses, as bedside care requires clinical judgment and empathy; addressing burnout, turnover, and workforce sustainability through flexible staffing and targeted technology is critical to mitigating projected global nursing shortages.
One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough
February 17, 2026 / natural killer cell therapy / CAR-NK cell engineering / stem cell immunotherapy / cord blood NK cells / cancer cell immunotherapy
Researchers engineered cord blood–derived stem cells to generate millions of potent natural killer cells, including CAR-modified variants, enabling scalable production of tumor-targeting immunotherapies with potential applications across hematologic and solid malignancies.
Boehringer axes inhaled gene therapy after viewing cystic fibrosis data
February 17, 2026 / cystic fibrosis gene therapy / inhaled lentiviral vector / CF clinical trial failure / pulmonary gene therapy development / mRNA therapy cystic fibrosis
Boehringer Ingelheim discontinued its inhaled lentiviral gene therapy for cystic fibrosis after Phase 1/2 data failed to support further development, highlighting ongoing challenges in advancing pulmonary gene and mRNA therapies for CF.
Mass General Brigham evaluates emerging healthcare technologies
February 17, 2026 / emerging healthcare technologies / digital health innovation / clinical workflow integration / healthcare technology evaluation / health system scalability
Mass General Brigham evaluates emerging healthcare technologies by integrating operational feasibility, clinical value, and scalability considerations, emphasizing balanced innovation that aligns digital health solutions with real-world clinical workflows and system-wide implementation needs.
// 4th Industrial Revolution
GE HealthCare, BARDA ink $35M expansion to AI-enabled imaging deal
February 18, 2026 / AI-enabled ultrasound / trauma care imaging / BARDA contract healthcare / point-of-care diagnostics / artificial intelligence radiology
GE HealthCare secured a $35 million BARDA contract expansion to advance AI-enabled ultrasound tools aimed at improving rapid trauma diagnosis and supporting non-expert users, enhancing point-of-care imaging accessibility and emergency clinical decision-making.
VCU Health on hospital-at-home and RPM governance
February 18, 2026 / hospital-at-home programs / remote patient monitoring governance / digital health transformation / EHR integration strategy / home-based acute care
VCU Health highlights governance strategies for hospital-at-home and remote patient monitoring programs, emphasizing EHR integration, workflow optimization, vendor collaboration, and sustainable digital transformation to expand acute and NICU care delivery in home-based settings.
AI analyzes ECG to predict ventricular remodeling in patients with repaired tetralogy of Fallot
February 11, 2026 / AI ECG analysis / tetralogy of Fallot / ventricular remodeling prediction / cardiac MRI alternative / congenital heart disease monitoring
A multicenter AI model analyzing routine ECGs identified ventricular remodeling risk in patients with repaired tetralogy of Fallot, offering a scalable alternative to cardiac MRI for risk stratification and follow-up, though site-specific validation remains essential before clinical implementation.
New technology maps protein production across individual brain cells
February 18, 2026 / Ribo-STAMP technology / single-cell protein translation / hippocampus research / neurological disease mechanisms / mRNA isoform regulation
Researchers developed Ribo-STAMP, enabling single-cell mapping of protein translation in nearly 20,000 mouse hippocampal cells. The study revealed cell-type differences, isoform-specific translation, and distinct neuronal translation states, offering new insights into memory circuits and neurological disease mechanisms.
AI is slashing jobs across industries. Will pharma be next?
February 18, 2026 / AI in pharma / biopharma workforce trends / AI drug discovery jobs / pharmaceutical industry employment / machine learning in life sciences
Despite widespread AI-driven layoffs in other industries, biopharma is using artificial intelligence to reshape—not eliminate—jobs. AI is expanding roles in drug discovery, analytics, and cross-functional teams, emphasizing new skill sets rather than workforce reduction.
// Business & Markets
Daffodil Health Secures $16.3M for Health Plan Administration Platform
Feburary 17, 2026 / AI health plan administration / claims processing automation / out-of-network repricing / payment integrity platform / healthcare cost transparency
Daffodil Health raised $16.3 million to scale its AI-driven health plan administration platform, automating out-of-network claims repricing and payment integrity. The SaaS solution enhances transparency, cost control, and operational efficiency for payers and third-party administrators.
GSK strikes 5-year deal with Jackson Laboratory focused on neurodegenerative disease research
Feburary 18, 2026 / neurodegenerative disease research / Alzheimer’s stem cell models / patient-derived pluripotent stem cells / drug discovery collaboration / predictive disease modeling
GSK entered a five-year collaboration with JAX-NYSCF to develop advanced patient-derived stem cell models for neurodegenerative diseases, including Alzheimer’s. The partnership aims to improve disease modeling, enhance target validation, and accelerate discovery of predictive, personalized therapies.
Merck to Leverage Mayo Clinic Platform_Orchestrate for AI-Enabled Drug Discovery
February 18, 2025 / AI-enabled drug discovery / real-world evidence platform / multimodal clinical data / inflammatory bowel disease research / precision medicine collaboration
Merck and Mayo Clinic formed a strategic partnership to use AI and multimodal, real-world clinical data from Mayo’s Platform_Orchestrate to enhance drug discovery in inflammatory bowel disease, atopic dermatitis, and multiple sclerosis through improved target identification and validation.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance
February 18, 2026 / PI3K pathway inhibition / multi-node cancer therapy / endometrial cancer clinical trial / AKT mTOR targeted therapy / oncology drug development
Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million to advance PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor. Early trials showed a 71% response rate in PI3K-mutated cancers, supporting further Phase 2 development in endometrial and breast cancer.
Rainfall Health Raises $15M to Turn CMS Team Mandates into Revenue
February 18, 2026 / CMS TEAM model / value-based care compliance / AI healthcare platform / surgical outcomes reimbursement / post-acute care quality metrics
Rainfall Health raised $15 million to scale its AI-driven compliance platform supporting CMS’s TEAM model, which links reimbursement to surgical outcomes. By standardizing post-acute data and quality reporting, hospitals may increase revenue up to 20% across five high-cost procedures.
// Legal & Regulatory
FDA accepts filing for Moderna flu vaccine after swift rethink
February 18, 2026 / Moderna mRNA 1010 flu vaccine / FDA accelerated approval pathway / influenza vaccine immunogenicity / ACIP senior flu recommendations / mRNA influenza vaccine filing
The FDA accepted Moderna’s amended mRNA-1010 influenza vaccine filing after initially issuing a refusal-to-file letter. The revised application seeks full approval for adults 50–64 and accelerated approval for those ≥65, positioning potential launch ahead of the 2026–27 flu season.
Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug
February 18, 2026 / IL 6 inhibitor therapy / clazakizumab monoclonal antibody / cardiovascular inflammation treatment / cardiometabolic drug development / atherosclerotic cardiovascular disease pipeline
Eli Lilly will pay $100 million for rights to clazakizumab, an IL-6–targeting monoclonal antibody from CSL, expanding its cardiometabolic pipeline. The drug, in Phase 3 for cardiovascular risk in kidney disease, reflects growing interest in inflammation-driven cardiovascular therapies.
US FDA’s Push For Greater Transparency: What About Advisory Committees?
February 18, 2026 / FDA regulatory transparency / advisory committee meetings / complete response letter disclosure / drug approval process / FDA action package release
An FDA proposal to release full action packages instead of only complete response letters highlights transparency concerns, particularly as fewer advisory committee meetings limit public insight into regulatory decision-making and the scientific rationale behind drug approvals or rejections.
Novartis heads to FDA with Rhapsido after phase 3 win in untapped chronic hives subtype
February 18, 2025 / remibrutinib BTK inhibitor / chronic inducible urticaria treatment / symptomatic dermographism therapy / phase 3 clinical trial results / FDA submission chronic hives
Novartis’ oral BTK inhibitor remibrutinib met Phase 3 endpoints in chronic inducible urticaria, achieving significantly higher complete response rates versus placebo. The company has filed for FDA approval in symptomatic dermographism, aiming to become the first targeted therapy for this condition.
FDA approves biosimilar for chemo-related infection risk
February 17, 2026 / Filkri filgrastim-laha / Neupogen biosimilar approval / chemotherapy-induced neutropenia / G-CSF biosimilar FDA / cancer infection risk treatment
The FDA approved Filkri (filgrastim-laha), a Neupogen biosimilar, to reduce infection risk in chemotherapy-induced neutropenia and related conditions. Approval was based on comparable pharmacokinetic, pharmacodynamic, safety and immunogenicity data from randomized studies in healthy adults.
// Research & Development
Viagra and shingles vaccine show surprising promise against Alzheimer’s
February 18, 2026 / Alzheimer’s disease prevention / shingles vaccine Zostavax / sildenafil Viagra dementia / drug repurposing neurology / neurodegenerative disease research
An international review of 80 existing drugs identified the shingles vaccine Zostavax, sildenafil (Viagra), and riluzole as leading candidates for repurposing in Alzheimer’s disease, highlighting immunologic and vascular pathways as potential targets for neurodegeneration prevention and treatment.
Subcellular localization as a driver of protein function
February 18, 2026 / subcellular protein localization / spatial proteomics research / protein moonlighting function / protein mislocalization disease / cell signaling and differentiation
This review examines how subcellular protein localization regulates cellular functions, including signaling, metabolism and differentiation. It highlights mechanisms governing localization, the concept of protein moonlighting, and how mislocalization contributes to cancer, neurodegeneration and autoimmunity, emphasizing advances in spatial proteomics.
Blood from pediatricians yields potential new medicines for respiratory viruses
February 18, 2025 / RSV neutralizing antibodies / human metapneumovirus therapy / antiviral monoclonal antibodies / respiratory virus prevention / immune-derived biologics
Researchers identified potent RSV and hMPV-neutralizing antibodies from pediatricians with heightened viral exposure. In rodent models, selected antibodies prevented infection and illness, supporting development of next-generation prophylactic or therapeutic agents for vulnerable populations lacking effective respiratory virus treatments.
Vascularized liver tissueoid-on-a-chip recreates tissue regeneration and transplant rejection
February 18, 2025 / liver tissueoid on a chip / transplant rejection model / vascularized liver organoid / immune-mediated allograft rejection / organ-on-chip technology
Researchers developed a vascularized liver tissueoid-on-a-chip that replicates human liver architecture, function, regeneration, and immune-mediated transplant rejection. The platform models allograft responses and cytokine activation, offering a physiologically relevant system for studying transplantation biology and testing immunosuppressive therapies.
Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity ‘silos’
February 18, 2025 / Zepbound tirzepatide / Taltz ixekizumab / psoriasis obesity treatment / PASI 100 clearance / phase 3b clinical trial
In a phase 3b trial, combining tirzepatide (Zepbound) with ixekizumab (Taltz) significantly improved complete skin clearance and ≥10% weight loss in obese psoriasis patients versus Taltz alone, supporting integrated treatment of inflammatory and metabolic comorbidities.
// Politics
Can Trump win over critics with MFN drug pricing plan? Former Biden advisor weighs in
February 18, 2026 / Most Favored Nation drug pricing / prescription drug cost reform / Medicare Medicaid drug prices / pharmaceutical price controls / US drug policy debate
President Trump’s Most Favored Nation drug pricing plan, tying U.S. prices to the lowest international rates, faces conservative opposition and transparency concerns, with critics warning of reduced innovation and access while confidential industry deals cloud projected impacts on Medicare and Medicaid.
Senate HELP Committee chair pitches proposals for FDA reform
February 18, 2026 / FDA reform proposal / accelerated approval pathway / rare disease drug regulation / biosimilar interchangeability policy / AI in healthcare regulation
Sen. Bill Cassidy’s FDA reform proposal calls for expanded novel trial designs, broader accelerated approvals beyond oncology, modernized rare disease and biosimilar regulations, and clearer AI oversight to enhance transparency, flexibility, U.S. competitiveness, and patient access to innovative therapies.
Red and blue states alike want to limit AI in insurance. Trump wants to limit the states.
February 18, 2026 / AI in health insurance / prior authorization algorithms / state AI regulation / health insurance claim denials / federal AI preemption policy
States across party lines are advancing laws to restrict health insurers’ use of AI in claims and prior authorization, citing transparency and patient safety concerns, while a Trump executive order seeks to preempt state regulation to promote AI innovation and federal control.
Where would Ireland be without big tech and pharma?
February 19, 2026 / Ireland pharmaceutical industry / corporate tax revenue Ireland / big pharma economic impact / multinational investment Ireland / life sciences sector Ireland
Ireland’s economy relies heavily on multinational tech and pharmaceutical companies, whose corporation tax contributions and employment support billions in public revenue and jobs, underscoring the country’s fiscal and workforce dependence on the life sciences and technology sectors.
PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations
February 15, 2026 / Pharmaceutical Benefits Scheme / PBAC reimbursement / GLP-1 weight loss therapy / Australia drug funding / PBS healthcare spending
Australia’s Pharmaceutical Benefits Scheme (PBS) spending is largely driven by PBAC reimbursement recommendations rather than direct fiscal policy decisions. Health Minister Mark Butler faces funding pressures following a recommendation to cover a GLP-1 weight-loss therapy, highlighting structural budget challenges in drug reimbursement.